FDA commissioner praises Eli Lilly Alzheimer's treatment results
May 03, 2023 at 18:56 PM EDT
Donanemab slowed the decline in memory, in thinking and in the ability to conduct daily activities by 35%, according to Lilly's data.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|